Pegvisomant and Sandostatin LAR Combination Study

To compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.

To compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.Condition:- AcromegalyStudy Type: InterventionalStudy Design: TreatmentEligibilityAges Eligible for Study: 18 Years and above, Genders Eligible for Study: BothCriteriaOther specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.Inclusion Criteria: * Diagnosis of acromegaly * Received previous radiation and/or surgical treatment for their GH (Growth Hormone) producing pituitary adenoma and have required medical therapy due to failure to normalize GH (Growth Hormone) and/or IGF-I as a result of their primary treatment * Patients that been receiving Sandostatin LAR for a minimum of 6 months prior to enrollmentExclusion Criteria: * Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or IGF-I concentrations * Patients on current medical therapy other than Sandostatin LAR * AST/ALT >= 3xULN (upper limits of normal) * Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI * Visual field defects (except post-surgical stable residual defects) * Unable to self administer drug * Radiotherapy within 12 months of entering the study[1] Australia, New South Wales Research Center, Darlinghurst, New South Wales, 2010, Australia; Recruiting[2] Australia, Victoria Research Center, Melbourne, Victoria, 3065, Australia; Recruiting